Kiora Pharmaceuticals, Inc. (KPRX) News
Follow Kiora Pharmaceuticals, Inc. (KPRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Kiora Licenses KIO-401 From Senju in Deal With Up to $168.5 Million in Milestones
Kiora Pharmaceuticals entered an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401 for ophthalmology uses in specified territories. Kiora will pay $3.5 million upfront; further pa
EQUITY | Oct 29, 2026, 11:13 AM UTC
L
Kiora appoints Keith Lane as executive vice president
Kiora named Keith Lane executive vice president and head of clinical development and regulatory affairs, effective September 8, 2026.
REGULATION | Sep 08, 2026, 11:13 AM UTC
H
Kiora Pharmaceuticals signs exclusive CKD license effective Aug. 20, 2026
Kiora Pharmaceuticals enters an exclusive license agreement with CKD effective August 20, 2026, with CKD paying Kiora $1M up-front and eligible for double digit royalties on KIO-301 net sales in South Korea.
MNA | Aug 19, 2026, 11:02 AM UTC